Bavarian Nordic — December 2020
-
We are disappointed this study did not meet the primary endpoint. However, we are encouraged by the meaningful reduction in hypoglycemic events observed with blinded CGM, and that all but one patient entered the long-term extension study,” stated Adam Steensberg, Chief Medical Officer at Zealand Pharma.
-
We remain committed to advancing dasiglucagon as a potential treatment of CHI due to the significant unmet medical need for these children, and will work closely with regulatory authorities to define the path forward while awaiting the outcome of the second phase 3 trial in younger children with CHI.”
-
Nogen holdning til det?
-
Det er ikke verdens undergang for Zealand, men dog nok til at det koster på tillid og kurs.
-
Tak
-
ditto:)
-
Nu har jeg fået læst det igennem, og jeg er helt sikker på, at markedet overreagerer
-
Tak @stockwatch1 - har selv suppleret 210ish
-
og enig
-
Det er vel spørgsmålet hvad disse to sætninger. Dasiglucagon on top of standard of care (SOC) did not significantly reduce the rate of hypoglycemia compared to SOC alone when assessed by intermittent self-measured plasma glucose (primary endpoint)
However, hypoglycemia was reduced by 40–50% with dasiglucagon as compared to SOC alone when assessed by blinded continuous glucose monitoring (exploratory analysis). -
Børsen - Zealand Pharma-chef efter kursdyk på 11 pct.: “Det mener jeg, er en overreaktion”
https://borsen.dk/nyheder/virksomheder/zealand-pharma-chef-vejen-bliver-lidt-mere-mudret-nu -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind